STI Stock Trade Intelligence
RHT

RESONANCE HEALTH LIMITED

Health Care · ASX:RHT
$0.0850
▼ -7.61%
Market cap
$41M
Turnover
$141,279
Last price
$0.0850
Day change
-7.61%
Announcements
15
Range, past year
Open 0.047 · Low 0.032 · Now 0.085 · High 0.099
Open RHT in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.

RHT momentum and trend analysis

Our analysis
Independent analysis generated by Stock Trade Intelligence as at 2026-11-16.
Momentum quality
71/100
Wyckoff phase
Distribution19d
Trend stage
Confirmed Uptrend
1 Day
-7.6%
1 Week
+10.4%
1 Month
+16.4%
1 Year
+73.5%
RSI
59
Avg daily range
5.9%

RESONANCE HEALTH LIMITED scores 71 out of 100 for momentum quality, a reading rated medium confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Confirmed Uptrend.

On the Wyckoff cycle it sits in Distribution, where it has been for 19 trading days. The weekly timeframe reads Uptrend, which does not yet agree with the daily view.

Against the wider market it is currently outperforming and the institutional accumulation signal reads moderate.

What stands out
  • Solid momentum quality (MQS 71)
  • Above SMA50 for 90 days
  • Volume 1.5× 60-day avg
  • RSI in healthy zone (59)
Points to watch
  • Risk rating: High
  • Composite downside risk elevated
Browse the whole market by signal:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highs

RHT announcements

Recent price-sensitive releases.
  • 2026-11-04 TrialsWest East-Coast Expansion - Executive Appointment Progress Report
  • 2026-10-28 Liver Fibrosis Device Webinar Presentation Company Presentation | Web Cast | Progress Report
  • 2026-10-27 $6.0 Million Placement Oversubscribed Placement
  • 2026-10-27 Investor Presentation Liver Fibrosis Device & Capital Raise Company Presentation
  • 2026-10-27 Liver Fibrosis Device - EPoC Study Results Trading Halt Lifted | Progress Report
  • 2026-10-23 Trading Halt Trading Halt
  • 2026-09-17 Global Strategic Alliance & MSA with Image Analysis Group Progress Report
Get the daily briefing The day's price-sensitive announcements, ranked by what actually moved, with our own momentum and cycle read on each.